BIOMARKER:

DNMT3A mutation

Entrez ID:

Related biomarkers:

‹

›

DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	azacitidine Resistant: B - Late Trials
DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	azacitidine Resistant: C2 – Inclusion Criteria
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	venetoclax + midostaurin Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	cytarabine Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	venetoclax + gilteritinib Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	venetoclax + sorafenib Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Myelodysplastic Syndrome MDS	decitabine Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	quizartinib Sensitive: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Chronic Myeloid Leukemia CML	YD312 Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	decitabine/cedazuridine Sensitive: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Colorectal Cancer CRC	sintilimab + fruquintinib Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	lenalidomide Resistant: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	EPZ-5676 Sensitive: D – Preclinical
DNMT3A mutation DNMT3A mutation	Acute Myelogenous Leukemia AML	ABBV-744 Sensitive: D – Preclinical